Endogenous pathology in tauopathy mice progresses via brain networks DOI Creative Commons
Denise M.O. Ramirez, Jennifer D. Whitesell, Nikhil Bhagwat

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: May 24, 2023

Neurodegenerative tauopathies are hypothesized to propagate via brain networks. This is uncertain because we have lacked precise network resolution of pathology. We therefore developed whole-brain staining methods with anti-p-tau nanobodies and imaged in 3D PS19 tauopathy mice, which pan-neuronal expression full-length human tau containing the P301S mutation. analyzed patterns p-tau deposition across established networks at multiple ages, testing relationship between structural connectivity progressive identified core regions early deposition, used propagation modeling determine link pathology strength. discovered a bias towards retrograde network-based tau. novel approach establishes fundamental role for propagation, implications disease.

Language: Английский

Inflammasome components as new therapeutic targets in inflammatory disease DOI
Rebecca C. Coll, Kate Schroder

Nature reviews. Immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 9, 2024

Language: Английский

Citations

27
Enhanced sandwich immunoassay based on bivalent nanobody as an efficient immobilization approach for foodborne pathogens detection DOI

Xingrui Liao,

Yao Zhang, Yifan Liang

et al.

Analytica Chimica Acta, Journal Year: 2024, Volume and Issue: 1289, P. 342209 - 342209

Published: Jan. 4, 2024

Language: Английский

Citations

17
Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years DOI Creative Commons

Elena Alexander,

Kam W. Leong

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 26, 2024

Nanobodies (Nbs) are antibody fragments derived from heavy-chain-only IgG antibodies found in the Camelidae family as well cartilaginous fish. Their unique structural and functional properties, such their small size, ability to be engineered for high antigen-binding affinity, stability under extreme conditions, ease of production, have made them promising tools diagnostics therapeutics. This potential was realized 2018 with approval caplacizumab, world's first Nb-based drug. Currently, Nbs being investigated clinical trials a broad range treatments, including targeted therapies against PDL1 Epidermal Growth Factor Receptor (EGFR), cardiovascular diseases, inflammatory neurodegenerative disorders Alzheimer's disease, Parkinson's amyotrophic lateral sclerosis. They also studied detecting imaging autoimmune conditions infectious diseases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A variety methods now available generate target-specific quickly efficiently at low costs, increasing accessibility. article examines these diverse applications roles. Only most recent articles published last five years been used summarize advanced developments field.

Language: Английский

Citations

10
Trends in nanobody technology in industrialization DOI Creative Commons

Yuhao Wu

Discover Nano, Journal Year: 2025, Volume and Issue: 20(1)

Published: Feb. 10, 2025

Antibodies, which are important research entities in the field of biopharmaceuticals, hold a key position global pharmaceutical market. Nanobodies [a single-domain antibody (VHH)] have gradually shown unique advantages due to their specificity, small molecule size, high affinity, good stability, flexible delivery routes, and fast tissue penetration. The importance nanobodies imaging, diagnosis, treatment diseases, especially tumors autoimmune is increasing. This review addresses technological hurdles, such as humanization, immunogenicity, production scalability, highlights novel strategies overcome these challenges, including PEGylation, fusion with long-lived serum proteins, advanced microbial expression systems. summarizes characteristics, production, industrialization nanobodies, nanobody-derived patents clinical trials, from 2014 2023. Finally, explores some challenges associated nanobody technology therapeutic interventions, diagnostic tools potential solutions.

Language: Английский

Citations

1
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines DOI Creative Commons

Liudmyla Maksymova,

Yannick A. Pilger,

Lutz Nuhn

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 4, 2025

Among the emerging strategies for cancer theranostics, nanomedicines offer significant promise in advancing both patients' diagnosis and treatment. In combination with nanobodies, can potentially enhance precision efficiency of drug or imaging agent delivery, addressing key limitations current approaches, such as off-target toxicities. The development will be further accelerated by creation smart nanoparticles, their integration immunotherapy. Obviously, success nano-immunotherapy depend on a comprehensive understanding tumor microenvironment, including complex interplay mechanisms that drive cancer-mediated immunosuppression immune escape. Hence, effective therapeutic targeting microenvironment requires modulation cell function, overcoming resistance associated stromal components extracellular matrix, and/or direct elimination cells. Identifying molecules involved progression is, therefore, essential developing therapies diagnostic tools predict patient responses to treatment monitor outcomes. Current are being designed careful consideration factors choice carrier (e.g., biocompatibility, controlled cargo release) moiety. unique properties nanobodies make them an engineering tool target biological high affinity specificity. this review, we focus latest applications various purposes. We also explore main types nanoparticles used immunotherapies, well formulating nanoparticle-nanobody conjugates. Finally, highlight how nanobody-nanoparticle formulations nanomedicines.

Language: Английский

Citations

1
Structural characterization of two nanobodies targeting the ligand-binding pocket of human Arc DOI Creative Commons
José M. Godoy Muñoz, Lasse Neset, Sigurbjörn Markússon

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(4), P. e0300453 - e0300453

Published: April 29, 2024

The activity-regulated cytoskeleton-associated protein (Arc) is a complex regulator of synaptic plasticity in glutamatergic neurons. Understanding its molecular function key to elucidate the neurobiology memory and learning, stress regulation, multiple neurological psychiatric diseases. recent development anti-Arc nanobodies has promoted characterization structure Arc. This study aimed validate two nanobodies, E5 H11, as selective modulators human Arc N-lobe (Arc-NL), domain that mediates several functions through peptide ligand binding site. structural characteristics recombinant Arc-NL-nanobody complexes were solved at atomic resolution using X-ray crystallography. Both bind specifically multi-peptide site Arc-NL. Isothermal titration calorimetry showed interactions occur nanomolar affinity, can displace TARPγ2-derived from Thus, both anti-Arc-NL could be used competitive inhibitors endogenous ligands. Differences CDR3 loops between indicate spectrum short linear motifs recognized by Arc-NL should expanded. We provide robust biochemical background support use attempts target Arc-dependent plasticity. Function-blocking eventually help unravel allow develop diagnostic treatment tools.

Language: Английский

Citations

7
Plasmonic enzyme immunoassay via nanobody-driven controllable aggregation of gold nanoparticles for detection of ochratoxin A in pepper DOI

Fujing Mao,

Zhenyun He,

Zhichang Sun

et al.

Food Chemistry, Journal Year: 2024, Volume and Issue: 453, P. 139623 - 139623

Published: May 13, 2024

Language: Английский

Citations

6
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders DOI Open Access
Sarfaraz K. Niazi, Zamara Mariam,

Matthias Magoola

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6683 - 6683

Published: June 18, 2024

Antibodies that can selectively remove rogue proteins in the brain are an obvious choice to treat neurodegenerative disorders (NDs), but after decades of efforts, only two antibodies Alzheimer’s disease approved, dozens testing phase, and one was withdrawn, other halted, likely due efficacy issues. However, these outcomes should have been evident since cannot enter sufficiently blood–brain barrier (BBB) protectant. all products be rejuvenated by binding them with transferrin, preferably as smaller fragments. This model tested quickly at a low cost applied bapineuzumab, solanezumab, crenezumab, gantenerumab, aducanumab, lecanemab, donanemab, cinpanemab, their paper demonstrates conjugating transferrin does not alter such amyloid-β (Aβ) α-synuclein. We also present selection conjugate designs will allow cleavage upon entering prevent exocytosis while keeping fragments connected enable optimal proteins. The identified readily returned patients lowest regulatory delays. These engineered manufactured recombinant engineering, mRNA technology, more affordable solution meet dire need effectively.

Language: Английский

Citations

6
Nanotechnology Approaches for Prevention and Treatment of Chemotherapy‐Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors DOI Creative Commons

Sarah Nevins,

Callan D. McLoughlin, Alfredo Oliveros

et al.

Small, Journal Year: 2023, Volume and Issue: unknown

Published: April 14, 2023

Nanotechnology has emerged as a promising approach for the targeted delivery of therapeutic agents while improving their efficacy and safety. As result, nanomaterial development selective targeting cancers, with possibility treating off-target, detrimental sequelae caused by chemotherapy, is an important area research. Breast ovarian cancer are among most common types in women, chemotherapy essential treatment modality these diseases. However, chemotherapy-induced neurotoxicity, neuropathy, cardiomyopathy side effects that can affect breast survivors quality life. Therefore, there urgent need to develop effective prevention strategies adverse effects. Nanoparticles (NPs) have extreme potential enhancing but require continued research elucidate beneficial interventions women survivors. In short, nanotechnology-based approaches preventing cardiomyopathy. NP-based drug systems therapeutics shown reducing chemotherapeutics efficacy. this article, latest nanotechnology discussed.

Language: Английский

Citations

16
A few good reasons to use nanobodies for cancer treatment DOI Creative Commons
Neema Ahishakiye Jumapili, Maida Živalj, Romina Mora Barthelmess

et al.

European Journal of Immunology, Journal Year: 2023, Volume and Issue: 53(9)

Published: June 27, 2023

Abstract mAbs have been instrumental for targeted cancer therapies. However, their relatively large size and physicochemical properties result in a heterogenous distribution the tumor microenvironment, usually restricted to first cell layers surrounding blood vessels, limited ability penetrate brain. Nanobodies are tenfold smaller, resulting deeper penetration reach cells poorly perfused areas. rapidly cleared from circulation, which generates fast target‐to‐background contrast that is ideally suited molecular imaging purposes but may be less optimal therapy. To circumvent this problem, nanobodies formatted noncovalently bind albumin, increasing serum half‐life without majorly size. Finally, shown superior qualities infiltrate brain tumors as compared mAbs. In review, we discuss why these features make prime candidates therapy of cancer.

Language: Английский

Citations

15